论文部分内容阅读
As the distinguished representative of metal-based drug,platinum based anticancer drugs have achieved great successes in cancer chemotherapy.However,poor selectivity towards cancer cells over normal cells is restricting their efficacy and causes severe side-effects.Improving therapeutic selectivity between cancer cells and normal cells is still a major goal in the development of anticancer agents.Non-platinum metal based anticancer complexes are attracting much attention,[1-2] especially ruthenium(Ru)complexes which have a rich redox chemistry(RuⅡ and RuⅢ),and exhibit a similar spectrum of kinetics to PtⅡ.